Beech Hill Advisors Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 5.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,414 shares of the biopharmaceutical company’s stock after selling 7,204 shares during the period. Pfizer comprises 2.5% of Beech Hill Advisors Inc.’s holdings, making the stock its 15th biggest holding. Beech Hill Advisors Inc.’s holdings in Pfizer were worth $4,550,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. TCW Group Inc. increased its position in shares of Pfizer by 8.2% in the second quarter. TCW Group Inc. now owns 169,072 shares of the biopharmaceutical company’s stock worth $6,133,000 after acquiring an additional 12,815 shares in the last quarter. Integrated Investment Consultants LLC increased its position in shares of Pfizer by 183.9% in the second quarter. Integrated Investment Consultants LLC now owns 117,997 shares of the biopharmaceutical company’s stock worth $1,587,000 after acquiring an additional 76,441 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Pfizer by 8.9% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,056,818 shares of the biopharmaceutical company’s stock worth $38,341,000 after acquiring an additional 85,928 shares in the last quarter. Cooke & Bieler LP purchased a new position in shares of Pfizer in the second quarter worth approximately $203,000. Finally, Mountain Capital Investment Advisors Inc increased its position in shares of Pfizer by 8.8% in the second quarter. Mountain Capital Investment Advisors Inc now owns 20,221 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 1,628 shares in the last quarter. 68.95% of the stock is currently owned by institutional investors.
PFE stock opened at $43.78 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41. The company has a market cap of $262.34 billion, a P/E ratio of 16.52, a P/E/G ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $45.81.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $0.67 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
PFE has been the topic of several analyst reports. JPMorgan Chase & Co. reissued a “$37.66” rating on shares of Pfizer in a research report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, July 11th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, July 3rd. BMO Capital Markets reissued a “buy” rating and issued a $42.00 target price on shares of Pfizer in a research report on Thursday, July 19th. Finally, Bank of America lifted their target price on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $42.40.
In related news, insider Sally Susman sold 40,381 shares of the firm’s stock in a transaction that occurred on Friday, July 20th. The shares were sold at an average price of $37.22, for a total transaction of $1,502,980.82. Following the completion of the sale, the insider now directly owns 155,377 shares in the company, valued at $5,783,131.94. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Ian C. Read sold 486,753 shares of the firm’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the sale, the chief executive officer now owns 1,145,693 shares of the company’s stock, valued at $42,803,090.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 761,230 shares of company stock valued at $29,054,690. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Leveraged Buyout (LBO)
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.